Class Action Lawsuit Filed Against Cerevel Therapeutics Holdings, Inc.:
On April 11, 2025, The Schall Law Firm announced that it had filed a class action lawsuit against Cerevel Therapeutics Holdings, Inc. (Cerevel) for alleged violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The lawsuit was brought on behalf of investors who purchased Cerevel’s shares between October 11, 2023, and August 1, 2024, or held shares during the record date of January 8, 2024, and sold them contemporaneously with Bain Capital Investors, LLC’s purchase on October 16, 2023.
Class Period and Eligible Investors:
The class period refers to the time frame during which the alleged securities law violations took place. In this case, it covers the period from October 11, 2023, to August 1, 2024. Eligible investors include those who bought Cerevel’s shares during this period, as well as those who held shares on the record date of January 8, 2024, and were entitled to vote on the merger of Cerevel and AbbVie Inc., and those who sold their Cerevel shares contemporaneously with Bain Capital Investors, LLC’s purchase on October 16, 2023.
Alleged Securities Law Violations:
The lawsuit alleges that Cerevel and certain of its executives and directors made false and misleading statements and failed to disclose material information during the class period. Specifically, it is claimed that the defendants misrepresented the safety and efficacy of Cerevel’s lead drug candidate, CER-101. The lawsuit further alleges that the defendants failed to disclose that the drug candidate’s clinical trial data was inconsistent and that there were safety concerns regarding its use.
Effect on Individual Investors:
If the allegations in the lawsuit are proven, investors who purchased Cerevel’s shares during the class period or sold their shares contemporaneously with Bain Capital Investors, LLC’s purchase may be able to recover their losses through the class action lawsuit. The amount of damages that may be recovered will depend on the specific circumstances of each investor’s case.
Effect on the World:
The class action lawsuit against Cerevel Therapeutics Holdings, Inc. highlights the importance of transparency and accuracy in the reporting of clinical trial data and the potential consequences for investors when such information is withheld or misrepresented. The lawsuit may also serve as a reminder for companies to ensure that they are providing timely and accurate information to the investing public.
Conclusion:
Investors who purchased Cerevel Therapeutics Holdings, Inc.’s shares between October 11, 2023, and August 1, 2024, or held shares during the record date of January 8, 2024, and sold them contemporaneously with Bain Capital Investors, LLC’s purchase on October 16, 2023, are encouraged to contact The Schall Law Firm before June 3, 2025, if they are interested in recovering their potential losses. The lawsuit alleges that the defendants made false and misleading statements and failed to disclose material information regarding the safety and efficacy of Cerevel’s lead drug candidate, CER-101. If the allegations are proven, investors may be able to recover their losses through the class action lawsuit. The lawsuit also serves as a reminder of the importance of transparency and accuracy in the reporting of clinical trial data and the potential consequences for investors when such information is withheld or misrepresented.
- Class Action Lawsuit:
- Cerevel Therapeutics Holdings, Inc.
- Violations of Securities Exchange Act of 1934
- October 11, 2023, to August 1, 2024, (Class Period)
- January 8, 2024, record date
- Contemporaneous sales with Bain Capital Investors, LLC’s purchase
- False and misleading statements
- Failure to disclose material information
- Transparency and accuracy in reporting clinical trial data
